Merck Sharp + Dohme Corp.

Merck Sharpe & Dohme Corp.

Shilpa Pandit

Jon H Condra

Ayesha Sitlani

Rose M Cubbon

Holly A Hammond

Yan Li

Pingyu Zhong

Feng Dong

Kevin Caili Wang

Jeffrey T Blue

Laurence B Peterson

Joseph C Santoro

Denise K Nawrocki

Sonia M Gregory

Henryk Mach

Dana D Wood

Timothy McCabe

Peter Peizhi Luo

Heidi Pixley

Peizhi (Peter) Luo

Heidi Yoder

Laura Orsatti

Yan Ni

Sharon Lobo

Carl P Sparrow

Xun Shen

Dale Lewis

Timothy Mccabe

Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

1B20 PCSK9 antagonists

Methods of using PCSK9 antagonists More specifically, methods for measuring circulating PCSK9 levels in a biological sample by means of an immunoassay The immunoassay used can be a solid phase immunoassay, such as a dissociation-enhanced lanthanide fluorescence immunoassay utilizing an E07 capture antibody or coating and a G08 or H23 detecting antibody.

PCSK9 immunoassay

1D05 PCSK9 antagonists

Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Antagonists of PCSK9

Growing community of inventors

Edison, NJ, United States of America

Shilpa Pandit